Centre for Chronic Disease Control

GSK's Arexvy remains ahead of its Pfizer RSV rival and isn't concerned with the potential entry of a new competitor. Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK and its leading Arexvy shot aren’t sweating. Over the first quarter, the vaccine once again came out ahead of Pfizer’s rival Abrysvo with 182 million pounds ($227 million) and some two-thirds of the RSV market share, GSK reported. In other terms, more than 70 million of the addressable U.S. population of 83 million have so far received GSK’s shot. Pfizer, meanwhile, posted quarterly Abrysvo sales of $145 million. It’s becoming a familiar story after the two raced to the FDA finish line last year. Since then, Arexvy has already collected blockbuster sales of 1.2 billion pounds ($1.5 billion) in its first year on the market. The company previously predicted peak sales to hit $3 billion, an estimate that GSK is “very confident” still stands, CEO Emma Walsmey said on a quarterly press call. Still, the U.K.-based drugmaker isn’t stopping there in its Arexvy development. As Walmsey noted on the call, “There is plenty of room for growth.” The next checkpoint is an FDA decision on the vaccine’s use in those aged 50 to 59, which would add another 50 million U.S. adults to its potential reach. The shot is currently approved for adults aged 60 and older. That decision is expected in June and would make Arexvy the first RSV vaccine approved for the age group. While the next couple of quarters likely won’t collect as many sales, since the RSV season typically picks up in the fall and peaks in the winter, growth over this year’s fourth quarter will be telling. By then, a third competitor—Moderna’s mRNA RSV vaccine—may have also entered the market, as its FDA decision date is set for this month. The Arexvy maker “welcomes competition,” Walmsey said, and remains “very confident” in the underlying demand for its vaccine, Chief Commercial Officer Luke Miels added on a call with analysts. A clearer picture on the potential impact of Moderna’s entry will come when the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices makes its immunization recommendations. That decision will begin “a race to lock down contracts” ahead of the next RSV season, Miels added. In its Arexvy journey, GSK can look to its established shingles vaccine, Shingrix. That shot collected 945 million pounds ($1.2 billion) over the quarter, 50% of which came from global sales. Together, the vaccines led GSK’s wider vaccine profile to 16% growth. Elsewhere, specialty medicines demonstrated similar growth of 17%, while general medicines crawled up 1%. The three sectors brought in largely even hauls of 2.3 billion pounds ($2.8 billion), 2.5 billion pounds ($3.1 billion) and 2.6 billion pounds ($3.2 billion), respectively. All in all, the company garnered total quarterly revenues of 7.4 billion pounds ($9.2 billion) and boosted its 2024 guidance to the upper end of its 5% to 7% forecast range.

Dive Brief:Pfizer on Thursday gained U.S. approval of its newest pneumococcal conjugate vaccine for use in children and infants, helping it compete with a rival shot from Merck & Co. that won a similar OK last year.Pfizers vaccine, called Prevnar 20, is designed to protect against infection by 20 strains of the bacteria seven more than the companys prior Prevnar 13 version. It has been approved in adults since 2021.Last July, Merck won approval in children of its Vaxneuvance vaccine, which protects against 15 strains. Both companies could soon face more competition as the market has sparked interest from other drugmakers.Dive Insight:While vaccines for the bacterial infection are widely available, thousands of cases still lead to hospitalization and death in the U.S. each year. In response, Pfizer, Merck and others have worked to develop new shots that offer better protection, particularly against strains that werent previously covered by Prevnar 13.These second-generation shots are meant to improve upon older versions like Mercks Pneumovax 23, which was first launched in 1983. That companys follow-on, Vaxneuvance, gained clearance in adults in 2021 and a year later won expanded use in children aged 6 weeks through 17 years.Pfizers latest approval was supported by clinical testing that compared Prevnar 20 to Prevnar 13. The company reported positive Phase 3 results in August. The trial was one of several to indicate the shot worked just as well and was safe in infants and children. In the trial, immune responses were evaluated one month after a third and fourth dose of the vaccine. Immune responses were compared to those with Prevnar 13.Other vaccine developers aim to get involved, too. Biotechnology company Vaxcyte recently reported positive Phase 2 study results for an experimental vaccine its developing in older adults. The company said immune responses were comparable to Pfizers Prevnar 20, and that it will start Phase 3 testing later this year.Meanwhile, GSK is testing a shot it gained through a $2.1 billion acquisition of Affinivaxlast May.The Center for Disease Controls advisory committee on immunization practices is set to hold a meeting in June, when it could discuss immunization recommendations. '

Diabetes to Occupy Over 28% of Digital Therapeutics Share; Sales in Obesity to Surge by 2x by 2032 The digital therapeutics market analysis offered by Fact.MR scrutinizes key growth factors that are impacting sales in the market. The report provides in-depth insights covering key factors such as drivers, opportunities, key players' strategies, and demand outlook. In addition to this, the study analyzes latest trends across various segments such as end-user, application, and regions. NEW YORK, Aug. 30, 2022 /PRNewswire/ -- The global digital therapeutics market is currently valued at US$ 5.27 Billion and is set to reach US$ 56.41 Billion by 2032. Sales in the market are projected to grow at 26.5% CAGR between 2022 to 2032. Growing use of digital therapeutics by leading pharma companies to improve health outcomes is a key factor driving the market. Further, accessibility to on-the-go internet and high penetration rate of smartphones has accelerated the demand for digital therapeutics in the pharmaceutical industry. Pharmaceutical companies around the world are aware of the massive growth potential of the digital therapeutics market. To capitalize on this, key companies are aiming for collaborations between pharmaceutical giants and leading tech companies. For instance, Sanofi and Happify signed an agreement in 2019 to bring prescription digital mental health therapeutics to individuals with multiple sclerosis. For more insights into the Market, Get A Sample of this Report! Adoption of digital therapeutics is also likely to be boosted by growing prevalence of chronic diseases such as diabetes, cancer, arthritis, and others. Due to the prevalence of these diseases, patients need constant monitoring and regular health check-ups. Hence, need for digital therapeutics is surging as awareness regarding health among patients continues to surge. According to the Center of Disease Control and Prevention (CDC), over 50% of the U.S. adults had at least one chronic condition in 2018 and the burden is rising with deteriorating lifestyle. As governments and healthcare providers focus on providing efficient, evidence-based care for chronic diseases, adoption of modern treatment processes such as digital therapeutics is likely to gain traction. Key Takeaways: North America is likely to be a prominent market, accounting for 42% share of the global market. Asia Pacific digital therapeutics market is likely to grow at a brisk pace of 20% CAGR between 2022 and 2032 owing to higher spending on healthcare by governments. Diabetes application segment is likely to account for 28% of demand share in digital therapeutics market By end-user, patients segment is likely to remain the largest during the forecast period. In terms of application, sales of digital therapeutics in obesity segment are anticipated to rise by 2x over the forecast period (2022-2032) Growth Drivers: Efficacy of digital therapeutics in improving treatment outcomes is likely to boost its adoption during the forecast period Increasing focus on preventative healthcare coupled with growing number of untreated and undiagnosed population will drive the demand in the market Rising prevalence of chronic diseases that demand long-term care such as cancer and diabetes are likely to create opportunities for digital therapeutics companies Restraints: Digital therapeutics is highly vulnerable to hacking attacks and phishing, putting patient health at risk. This factor is likely to create reluctance among patients until stringent safety measures are put into place Get Customization on this Report for Specific Research Solutions Competitive Landscape The digital therapeutics market is highly competitive with a presence of both established companies and new entrants. Market players are focusing on mergers & acquisitions and partnerships to consolidate their position. For instance, Teladoc partnered with National Labor Alliance in 2021 as part of its strategic goal of expanding its virtual care products and services Akili Interactive completed a merger with Social Capital Suvretta Holdings Corp in August 2022. The company also went public, trading under the ticker 'AKLI' on NASDAQ Key Companies Profiled by Fact.MR Voluntis Canary Health Fitbit Inc. Livongo Health, Inc. (Teladoc Health Inc.) Mango Health 2Morrow, Inc. Noom, Inc. Propeller Health WellDoc, Inc. Dexcom Pear Therapeutics Omada Health Inc. More Valuable Insights on Digital Therapeutics Market In the latest study, Fact.MR offers a detailed study on digital therapeutics market for the forecast period of 2022 to 2032. This study also highlights key drivers promoting the sales of digital therapeutics market with analysis across below segments: By Application Type: Diabetes Obesity Cardio Vascular Diseases (CVD) Respiratory Diseases Smoking Cessation CNS Diseases By End User: Patients Providers Payers Employers By Region: North America Latin America Europe East Asia South East Asia & Oceania Middle East & Africa Interested to Procure The Data? Inquire here Key Questions Covered in the Digital Therapeutics Market: What is the projected value of the digital therapeutics market in 2022? At what rate will the global digital therapeutics market grow until 2032? Which are the factors hampering the growth in the digital therapeutics market? Which region is expected to lead in the global digital therapeutics market during 2022-2032 Which are the factors driving the digital therapeutics during the forecast period? What is the expected market value of digital therapeutics during the forecast period? Explore Fact.MR's Coverage on the Technology Domain 5G Services Market - The global 5G services market size is anticipated to procure a market value of US$ 48 billion in 2022 and is likely to reach US$ 3,827.64 billion. Sales in the market are poised to expand at an impressive CAGR of 55% from 2022 to 2032. Growth in the market is primarily attributed to increasing development in virtualization and growing need for AR/VR in in diverse industries. Real-Time Payments Market - The real-time payments market is expected to garner a market value of US$ 16 billion in 2022, and is likely to register staggering growth at a CAGR of 33% in the forecast period 2022-2032. Increasing use of e-wallets for transaction across multiple domains such as BFSI, retail, travel, and others is improving the demand in the market. Digital Remittance Market - The digital remittance market is expected to reach a valuation of US$ 18.16 billion in 2022 and register a positive CAGR of 13.5% in the forecast period 2022-2032. Fact.MR further offers a bird-eye 360-degree view of key trends and opportunities propelling the growth in the market across key regions over the upcoming decade. Digital Battlefield Market: North America accounts for approximately 39% of the global sales value of digital battlefields. AI innovations in digital battlefields in the defense sector will be key to the growth of market players over the coming years. Digital Transformation Market : Digital Transformation Market Analysis by Technology (Cloud Computing, Big Data and Analytics, Mobility/ Social Media, Cybersecurity), by Deployment (Cloud, On-premises), by Organization Size, by Vertical, by Region - Global Forecast 2022-2032 Check it Out More Reports by Fact.MR on Technology Industry About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That's why focus on offering insights that can actually make a difference to bottom-lines. Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: [email protected] Follow Us: LinkedIn | Twitter | Blog Logo: SOURCE Fact.MR